Astragalus / PIK3CA Cancer Research Results

AG, Astragalus: Click to Expand ⟱
Features:

Astragalus — Astragalus (AG; typically Astragalus membranaceus root, “Huangqi”) is a traditional botanical immunomodulator composed of multiple bioactive fractions, notably astragaloside IV (AS-IV; triterpenoid saponin), Astragalus polysaccharides (APS; high–molecular-weight glycans), and flavonoids. It is best classified as a multi-constituent herbal drug (botanical) whose dominant functional identity is immune regulation with secondary inflammation- and stress-response tuning. Common abbreviations include AG, AS-IV, and APS. In oncology contexts it is most often positioned as adjunct/supportive care rather than a validated standalone anticancer agent.

Primary mechanisms (ranked):

  1. Immune modulation with enhanced innate/adaptive effector function (macrophage, NK, T-cell activity; context-dependent antitumor immunity)
  2. Checkpoint and tumor–immune interface modulation (e.g., PD-L1 downregulation reported for APS in some models)
  3. Inflammation pathway tuning (NF-κB and cytokine networks; bidirectional depending on immune context)
  4. Growth/survival signaling modulation (PI3K/Akt/mTOR and MAPK; model- and constituent-dependent)
  5. EMT/migration programs (Wnt/β-catenin axis suppression reported in some tumor models)
  6. Redox/stress-response effects (ROS buffering and NRF2 activation are commonly reported; may be protective rather than directly cytotoxic)

Bioavailability / PK relevance: Constituent-dependent. AS-IV has low oral bioavailability and limited systemic exposure in typical oral-use scenarios; APS are poorly absorbed and are more plausibly active via gut–immune signaling and downstream immunomodulation rather than direct tumor exposure. Extract variability (species, processing, standardization) is a major translational confounder.

In-vitro vs systemic exposure relevance: Many mechanistic cancer studies use purified AS-IV or APS at concentrations unlikely to reflect achievable human plasma levels from typical oral extracts; immune-mediated and gut–immune mechanisms are often more plausible clinically than direct concentration-driven tumor cell cytotoxicity.

Clinical evidence status: Human evidence is strongest for adjunctive use alongside standard therapy (quality-of-life, fatigue, immune parameters, and some meta-analyses reporting improved response/toxicity profiles in specific settings). Robust evidence for standalone anticancer efficacy is not established.

Astragalus is an herb that has been used in traditional Chinese medicine for centuries.It has many purported health benefits, including immune-boosting, anti-aging and anti-inflammatory effects.
Astragalus (AG; commonly referring to Astragalus membranaceus root; major constituents: astragaloside IV [AS-IV], polysaccharides [APS], flavonoids) is a traditional botanical immunomodulator. Its dominant biology is immune modulation and stress-adaptive signaling, ranking conceptually as:
(1) immune activation/regulation (macrophage, NK, T-cell modulation),
(2) NF-κB and inflammatory pathway tuning,
(3) PI3K/Akt/mTOR and MAPK context-dependent signaling, and
(4) NRF2-mediated cytoprotection/antioxidant effects.
Bioavailability is variable and constituent-dependent; AS-IV has relatively low oral bioavailability, APS are high-molecular-weight and act largely via gut–immune interaction. Many in-vitro cancer studies use purified compounds at concentrations exceeding typical plasma levels. Clinical evidence exists primarily as adjunctive oncology support (quality-of-life, immune parameters); robust standalone anticancer efficacy is not established. Immune stimulation may enhance antitumor surveillance but effects are tumor- and context-dependent.

Astragalus (AG) — Cancer-Relevant Pathway Effects

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Immune Activation ↑ immune-mediated cytotoxicity (context-dependent) ↑ immune competence G Immunomodulation APS frequently show macrophage/NK/T-cell modulation in preclinical systems; clinical positioning is commonly adjunctive/supportive.
2 PD-1 / PD-L1 Axis ↓ PD-L1 (model-dependent); ↑ antitumor immunity ↔ R–G Immune checkpoint interface APS has been reported to reduce PD-L1–mediated immunosuppression in some tumor models; translation to clinical checkpoint therapy remains uncertain.
3 NF-κB Signaling ↓ NF-κB (tumor-promoting inflammation; context-dependent) ↔ / balanced activation R–G Inflammatory pathway tuning Commonly described as anti-inflammatory in many models, but immune-activation contexts can require transient inflammatory signaling.
4 PI3K/Akt/mTOR ↓ Akt/mTOR signaling (model-dependent) ↔ / survival support (context-dependent) R–G Anti-proliferative signaling Often demonstrated with purified constituents and/or higher in-vitro concentrations; may contribute to growth suppression in select models.
5 MAPK Axis ↓ ERK; ↑ JNK/p38 (stress/apoptosis; model-dependent) ↔ adaptive stress response R Stress-response reshaping Directionality varies by fraction (AS-IV vs APS vs flavonoids), tumor type, and dose.
6 Wnt / β-catenin and EMT ↓ Wnt/β-catenin; ↓ EMT; ↓ migration/invasion (model-dependent) ↔ G Anti-metastatic phenotype shift Reported in several preclinical models; relevance depends on whether adequate exposure and target engagement occur in vivo.
7 Glycolysis and HIF-1α ↓ glycolysis / ↓ lactate (model-dependent) ↔ R–G Metabolic downshift Metabolic effects are described in some models, but may be secondary to upstream signaling and inflammatory-state changes.
8 Angiogenesis ↓ pro-angiogenic signaling (model-dependent) ↔ G Anti-angiogenic tendency Evidence is preclinical and heterogeneous; may be indirect via NF-κB/cytokine modulation.
9 ROS Modulation ↓ ROS (dose-dependent) ↓ ROS (protective) P–R Redox buffering Can be supportive for normal-tissue protection; may be counterproductive if combined with therapies relying on oxidative cytotoxicity (context-dependent).
10 NRF2 Axis ↑ NRF2 (context-dependent) ↑ NRF2 (cytoprotection) R–G Antioxidant gene induction NRF2 activation can protect normal tissues but may also support tumor stress tolerance in some contexts; mechanistic centrality varies by fraction.
11 Chemosensitization ↑ chemo-sensitization reported (model-dependent) ↑ tolerance to toxicity (context-dependent) G Adjunct compatibility Clinical literature is mixed and highly formulation-specific; some meta-analyses suggest improved tolerance and response when combined with standard regimens in selected settings.
12 Clinical Translation Constraint Constituent variability; low AS-IV oral exposure; APS primarily gut–immune; in-vitro dosing often non-physiologic; interaction risk with immunosuppressants/anticoagulants — Heterogeneity / PK Most credible clinical role is adjunct/supportive care with careful attention to product standardization and drug–herb interaction risk.
TSF Legend: P: 0–30 min   R: 30 min–3 hr   G: >3 hr


Astragalus — In Alzheimer’s disease (AD) and broader neurodegeneration models, Astragalus fractions (notably AS-IV and flavonoids; sometimes APS indirectly) are most often described as cytoprotective via anti-inflammatory and antioxidant programs, with secondary support of pro-survival signaling and mitochondrial stability. Evidence is primarily preclinical; high-quality AD RCT efficacy remains unestablished.

Primary mechanisms (ranked):

  1. Oxidative stress reduction and cellular stress buffering (context-dependent)
  2. Neuroinflammation suppression (microglial and NF-κB-linked cytokine modulation)
  3. Pro-survival signaling support (e.g., PI3K/Akt in injury/neurodegeneration models; context-dependent)
  4. Mitochondrial stabilization and metabolic support (model-dependent)

Bioavailability / PK relevance: AS-IV systemic exposure is limited with typical oral dosing; CNS relevance depends on formulation and model. Many findings use purified compounds and dosing not directly comparable to common supplement use.

In-vitro vs systemic exposure relevance: Numerous neuronal studies employ concentrations/doses that may exceed achievable CNS exposure; interpretation should emphasize direction-of-effect rather than assuming clinical target engagement.

Clinical evidence status: Predominantly preclinical; insufficient robust AD-specific RCT evidence for disease-modifying benefit.

Astragalus (AG) — Alzheimer’s Disease (AD)-Relevant Effects

Rank Pathway / Axis AD Context TSF Primary Effect Notes
1 Oxidative Stress ↓ neuronal ROS (context-dependent) P–R Neuroprotection Often attributed to flavonoids/AS-IV in model systems; translation depends on exposure and disease stage.
2 Neuroinflammation ↓ microglial activation; ↓ inflammatory cytokines (model-dependent) R–G Anti-inflammatory Commonly framed through NF-κB-linked pathways in preclinical literature.
3 PI3K/Akt Survival Pathway ↑ neuronal survival signaling (context-dependent) G Pro-survival support Often studied in ischemia/toxicity paradigms rather than human AD pathology directly.
4 Mitochondrial Function ↑ mitochondrial stability (model-dependent) R–G Energy support Reported improvements in mitochondrial dynamics/oxidative injury markers in some models.
5 Clinical Translation Constraint No robust AD RCT efficacy data — Evidence gap Current evidence is insufficient to claim disease-modifying clinical benefit in AD.
TSF Legend: P: 0–30 min   R: 30 min–3 hr   G: >3 hr
PIK3CA, phosphoinositide-3-kinase, catalytic, alpha polypeptide: Click to Expand ⟱
Source: CGL-Driver Genes
Type: Oncogene
Class III PtdIns3K (PIK3C3/Vps34)
Class I phosphoinositide 3-kinase (PI3K)
In contrast to the class III PtdIns3K as a positive regulator of autophagy, class I PI3K-AKT signaling has an opposing effect on the initiation of autophagy.

PIK3CA is a gene that encodes the p110α catalytic subunit of phosphoinositide 3-kinase (PI3K), which is a key player in the PI3K/AKT signaling pathway. This pathway is crucial for various cellular processes, including growth, proliferation, survival, and metabolism.
PIK3CA is often overexpressed, which can lead to increased activity of the PI3K/AKT signaling pathway. This overexpression can contribute to tumor growth, survival, and metastasis.

Class III PtdIns3K (PIK3C3/Vps34) is central to autophagy regulation. In many tumor types, higher expression is thought to promote autophagy, which can help cancer cells survive under metabolic and therapeutic stress. This survival advantage is one reason why high PIK3C3 expression sometimes correlates with a more aggressive phenotype and poorer overall prognosis.
Scientific Papers found: Click to Expand⟱
1338- AG,    The Modulatory Properties of Astragalus membranaceus Treatment on Triple-Negative Breast Cancer: An Integrated Pharmacological Method
- in-vitro, BC, NA
TumCI↓, Apoptosis↑, Symptoms↓, PIK3CA↓, Akt↓, Bcl-2↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

PIK3CA↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 1,   Bcl-2↓, 1,  

Migration ⓘ

TumCI↓, 1,  

Functional Outcomes ⓘ

Symptoms↓, 1,  
Total Targets: 6

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: PIK3CA, phosphoinositide-3-kinase, catalytic, alpha polypeptide
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:37  Target#:256  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page